Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
UBS
US Department of Justice
Healthtrust
Queensland Health
AstraZeneca

Generated: September 18, 2019

DrugPatentWatch Database Preview

Patent: 10,058,621

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,058,621
Title:Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
Abstract: The present invention relates to combination therapy with drugs, such as Bruton\'s tyrosine kinase inhibitors or PI3K inhibitors, with antibodies or ADCs against HLA-DR. Where ADCs are used, they preferably incorporate SN-38 or pro-2PDOX. The ADC may be administered at a dosage of between 1 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth.
Inventor(s): Goldenberg; David M. (Mendham, NJ), Cardillo; Thomas M. (Cedar Knolls, NJ)
Assignee: Immunomedics, Inc. (Morris Plains, NJ)
Application Number:15/484,308
Patent Claims:see list of patent claims

Details for Patent 10,058,621

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Try a Free Trial Immunomedics, Inc. (Morris Plains, NJ) 2035-06-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Fish and Richardson
Accenture
McKesson
Healthtrust
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.